Immix Biopharma to present interim NXC-201 data from 45‑patient CAR‑T trial at ASH 2026
Immix Biopharma announced that it will share safety and efficacy results from its NXC-201 CAR‑T program in a 45‑patient study (NEXICART‑2) at the American Society of Hematology's 68th Annual Meeting on December 14, 2026. The trial is the first U.S. investigation of CAR‑T therapy for relapsed or refractory AL amyloidosis. NXC-201 has already earned Breakthrough Therapy, Regenerative Medicine Advanced Therapy and Orphan Drug designations from the FDA and EMA. The presentation will occur in New Orleans, Louisiana.
Why it matters
The data could influence investor sentiment toward Immix, as positive interim results may support the company's upcoming registrational filing. Analysts will watch the ASH presentation for signals on the therapy's safety profile and efficacy trends.
Key facts
- 1Immix will present an abstract on NXC-201 at the ASH 68th Annual Meeting in New Orleans, LA. investingnews.com
- 2The presentation is scheduled for Monday, December 14, 2026 at 11:15 AM Central Time. investingnews.com
- 3The NEXICART‑2 trial includes 45 patients with relapsed/refractory AL amyloidosis. investingnews.com
- 4NXC-201 has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug Designation from the U.S. FDA and EMA. investingnews.com
- 5The U.S. relapsed/refractory AL amyloidosis patient pool is estimated at about 30,506 in 2026, growing at roughly 12 % per year. investingnews.com
- 6The amyloidosis market was $6.2 billion in 2025 and is projected to reach $6.6 billion in 2026. investingnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.